Patients like dietitians to adopt a patient-centred approach, which might be either patient- or practitioner-led, and to take account of what they wanted from consultations, adapting these to meet their individual requirements.

treatment (P < 0.001) with a mean weight loss of 2.8 kg (0.6). BMI was significantly lower after 6 months (P < 0.001) with a mean reduction of 1.5 kg m )2 (1.9). HbA 1C was also significantly reduced after 6 months (P < 0.001) with a mean reduction of 1.7% (1.5). Changes in weight, BMI and HbA 1C were not significantly different between genders, time since diagnosis or age. The audit identified that the Diabetes team were following NICE guidelines for the majority of the time. When starting the drug, 100% of patients were commenced as a third line therapy, 96% of patients had a HbA 1C ‡7.5%, and 77% had a BMI ‡35 kg m )2 . Eighty seven percent of patients had associated psychological or medical problems and 38% were started on Byetta due to occupational implications of insulin or to promote weight loss. Of those patients that continued the drug after 6 months, 60% had achieved the recommended 1% reduction in HbA 1C and 89% had shown a 3% reduction in weight. Conclusion: After 6 months, Byetta therapy was associated with significant reductions in weight, BMI and HbA 1C , which supports the findings of previous research (Buse et al., 2004; DeFronzo et al., 2005). This audit did not include a control group, and future studies could compare the outcomes of treatment with Byetta against outcomes after conventional treatment. The management of patients on Byetta followed the NICE guidance for the majority of the time. However, data for some patients was missing from 'Diabeta', suggesting that staff were not always recording information after each consultation with the patient. In future, a larger sample size would increase the validity of results, and future audits within the hospital could focus on record keeping. References: Buse J.B., Henry R.R., Han J. et al. (2004) Effects of exenatide (exendin-4) on glycaemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27, 2628-2635. DeFronzo R.A., Ratner R.E., Han J. et al. (2005) Effects of exenatide (exendin-4) on glycaemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.